EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

Shivaani Kummar iD, Lin Shen iD, David S Hong, Ray McDermott, Vicki L Keedy, Michela Casanova, George D Demetri, Afshin Dowlati, Soledad Gallego Melcón, Ulrik N Lassen, Serge Leyvraz, Tianshu Liu und 12 weitere

Cancer · 2023-12 · 129 (23) · 3772-3782

DOI: 10.1002/cncr.35036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 28.09.2023. Verfasst von Shivaani Kummar und 23 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cancer Center, Stanford University, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Sarcoma, Neoplasms, Soft Tissue Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Larotrectinib, a first‐in‐class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with various solid tumors harboring NTRK gene fusions. This subset analysis focuses on the efficacy and safety of larotrectinib in an expanded cohort of adult patients with TRK fusion sarcomas.

Methods

Patients (≥18 years old) with sarcomas harboring NTRK gene fusions were identified from three clinical trials. Patients received larotrectinib 100 mg orally twice daily. Response was investigator‐assessed per RECIST v1.1. Data cutoff was July 20, 2021.

Results

At the data cutoff, 36 adult patients with TRK fusion sarcomas had initiated larotrectinib therapy: two (6%) patients had bone sarcomas, four (11%) had gastrointestinal stromal tumors, and 30 (83%) had soft tissue sarcomas. All patients were evaluable for response and demonstrated an objective response rate of 58% (95% confidence interval, 41–74). Patients responded well to larotrectinib regardless of number of prior lines of therapy. Adverse events (AEs) were mostly grade 1/2. Grade 3 treatment‐emergent AEs (TEAEs) occurred in 15 (42%) patients. There were no grade 4 TEAEs. Two grade 5 TEAEs were reported, neither of which were considered related to larotrectinib. Four (11%) patients permanently discontinued treatment due to TEAEs.

Conclusions

Larotrectinib demonstrated robust and durable responses, extended survival benefit, and a favorable safety profile in adult patients with TRK fusion sarcomas with longer follow‐up. These results continue to demonstrate that testing for NTRK gene fusions should be incorporated into the clinical management of adult patients with various types of sarcomas. Plain Language Summary Tropomyosin receptor kinase (TRK) fusion proteins result from translocations involving the NTRK gene and cause cancer in a range of tumor types. Larotrectinib is an agent that specifically targets TRK fusion proteins and is approved for the treatment of patients with TRK fusion cancer. This study looked at how well larotrectinib worked in adult patients with sarcomas caused by TRK fusion proteins. Over half of patients had a durable response to larotrectinib, with no unexpected side effects. These results show that larotrectinib is safe and effective in adult patients with TRK fusion sarcomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaNeoplasmsSoft Tissue NeoplasmsBone NeoplasmsHumansChildAdultAdolescentTropomyosinPyrazolesProtein Kinase InhibitorsGene FusionOncogene Proteins, FusionReceptor, trkAPyrimidines

Stichwörter der Autor:innen

NTRK gene fusionTRKTRK inhibitorslarotrectinibsarcoma

Substanzen

TropomyosinPyrazolesProtein Kinase InhibitorsOncogene Proteins, FusionReceptor, trkAlarotrectinibPyrimidines

Autor:innen und Institutionen

  • Stanford Cancer Center, Stanford University, Palo Alto, California, USA.
  • Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland.
  • Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

ORCID-Profile: Shivaani Kummar, Lin Shen, Victor Moreno

Förderung

  • NCI NIH HHS

Zitieren

APA

Kummar, S., Shen, L., Hong, D. S., McDermott, R., Keedy, V. L., Casanova, M., Demetri, G. D., Dowlati, A., Melcón, S. G., Lassen, U. N., Leyvraz, S., Liu, T., Moreno, V., Patel, J., Patil, T., Mallick, A. B., Sousa, N., Tahara, M., Ziegler, D. S., …, & Tan, D. S. W. (2023). Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer, 129(23), 3772-3782. https://doi.org/10.1002/cncr.35036

Vancouver

Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, et al. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer. 2023;129(23):3772-3782. doi:10.1002/cncr.35036

BibTeX
@article{Kummar2023,
  author = {Kummar, Shivaani and Shen, Lin and Hong, David S and McDermott, Ray and Keedy, Vicki L and Casanova, Michela and Demetri, George D and Dowlati, Afshin and Melcón, Soledad Gallego and Lassen, Ulrik N and Leyvraz, Serge and Liu, Tianshu and Moreno, Victor and Patel, Jyoti and Patil, Tejas and Mallick, Atrayee Basu and Sousa, Nuno and Tahara, Makoto and Ziegler, David S and Norenberg, Ricarda and Arvis, Pierre and Brega, Nicoletta and Drilon, Alexander and Tan, Daniel S W},
  title = {Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {23},
  pages = {3772--3782},
  doi = {10.1002/cncr.35036}
}
Kostenlos starten →